Connected Drug Delivery Device - Market Insights, Competitive Landscape, and Market Forecast - 2034
Description
Connected Drug Delivery Device Market Summary
Overview
Connected Drug Delivery Device Market Key Growth Drivers
The competitive landscape is led by the following active manufacturers:
Market Drivers
Rising Global Burden of Chronic Diseases
The most fundamental driver of the Connected Drug Delivery Device market is the rising global burden of chronic diseases that require long-term, precisely timed therapy. According to DelveInsight (2025), approximately 591 million people worldwide were living with diabetes, a number projected to surge to 854 million by 2050, a 46% increase, with type 2 diabetes accounting for over 90% of cases. Connected insulin pens, smart pumps, and continuous glucose monitoring systems are becoming indispensable for maintaining glycemic control, enabling patients to track glucose trends and adhere to insulin regimens while allowing providers to remotely fine-tune therapy. Similarly, an estimated 263 million people globally are affected by asthma, creating substantial demand for connected inhalers and nebulizers that monitor medication usage and transmit adherence data to clinicians. As the prevalence of these conditions rises, the volume and complexity of connected device adoption increases in step, sustaining demand through the forecast period.
Growth of Digital Health and Remote Patient Monitoring
The broader growth of digital health and remote patient monitoring is amplifying adoption of connected drug delivery devices. By leveraging mobile apps, Bluetooth Low Energy, NFC, and cloud-based platforms, these devices provide real-time visibility into medication usage and patient health metrics, enabling proactive clinical decision-making and supporting home-based care. This connectivity reduces the need for frequent hospital visits while giving healthcare providers continuous access to adherence and outcome data. For instance, in February 2025, Supernus Pharmaceuticals received FDA approval for ONAPGO, the first subcutaneous apomorphine infusion device for Parkinson's disease motor fluctuations, illustrating the expanding therapeutic scope of connected devices beyond diabetes and respiratory care.
Market Restraints
Despite strong momentum, the Connected Drug Delivery Device market faces material constraints. Data privacy and cybersecurity concerns are significant, as connected devices continuously transmit sensitive patient health information across mobile apps and cloud platforms, exposing manufacturers and providers to breach risk and regulatory scrutiny. The environmental impact of electronic waste from single-use and short-lifecycle connected components raises sustainability concerns and is drawing increasing regulatory attention. The relatively high price of connected devices compared with conventional, non-connected alternatives can limit adoption in cost-sensitive markets and among uninsured or underinsured patients. Interoperability challenges across competing Bluetooth, NFC, and proprietary platforms complicate integration with electronic health record systems, while building the digital health infrastructure and physician training needed for widespread adoption remains uneven across geographies. Together, these data-security, environmental, affordability, and infrastructure barriers temper the pace of growth, even as the underlying drivers of chronic disease burden, digital health expansion, and device innovation remain firmly intact.
Connected Drug Delivery Device Market Segment Analysis
The connected drug delivery device market by product (connected sensors [connected inhaler sensors and connectable injection sensors] and integrated connected devices [connected inhaler devices and connected injectable devices]), technology (Bluetooth, near-field communication (NFC), and others), end-user (hospitals & clinics, homecare settings, and others), and geography (North America, Europe, Asia-Pacific, and Rest of World).
By Product
Dominant Subsegment: Integrated Connected Devices.
The integrated connected devices segment accounted for 60% of the Connected Drug Delivery Device market in 2025. Within this segment, connected injectable devices hold the largest share, driven by the widespread adoption of smart insulin pens, auto-injectors, and wearable injectors. These devices are becoming the preferred choice for chronic disease management because they improve medication adherence, ensure precise dosing, and enable real-time monitoring of treatment outcomes. The incorporation of Bluetooth, NFC, and cloud-based platforms allows connected injectors to seamlessly transmit patient data to healthcare providers, enabling timely clinical interventions and personalized therapy adjustments, particularly for chronic conditions such as diabetes, multiple sclerosis, and rheumatoid arthritis. By facilitating at-home administration, connected injectable devices also reduce dependency on hospital visits, improving patient convenience and easing healthcare system burden. Ongoing innovation, including integrated sensors for dose verification and interoperability with mobile health apps and electronic health records, such as Medtronic's November 2024 FDA-cleared InPen update with missed meal dose detection, is further accelerating adoption. While connected sensors are growing steadily as an add-on retrofit category, the breadth, precision, and clinical integration of integrated connected devices secure the segment's leadership across the forecast period.
By Technology
Dominant Subsegment: Bluetooth.
The Bluetooth segment accounted for 64% of the Connected Drug Delivery Device market in 2025. The widespread adoption of Bluetooth, particularly Bluetooth Low Energy, has positioned it as the leading connectivity technology because of its low power consumption, seamless integration with smartphones, and ability to support real-time data transmission. Devices such as smart insulin pens, connected inhalers, and wearable injectors leverage Bluetooth to sync with mobile applications, enabling patients to track adherence, receive personalized reminders, and share treatment data with healthcare providers. For example, in May 2025, Oura introduced the Stelo glucose biosensor, a wearable device using Bluetooth to deliver real-time glucose data integrated into a broader health app, reinforcing the value of Bluetooth-enabled health ecosystems. Compared with NFC and other connectivity standards, Bluetooth remains the preferred choice because of its ubiquity across consumer devices, compatibility with digital health platforms, and reliable operation without continuous internet connectivity. Ongoing advancements in Bluetooth Low Energy protocols, offering extended range and improved energy efficiency, are expected to further reinforce its dominant position across the forecast period.
Connected Drug Delivery Device Market Region Analysis
Dominant Region: North America
North America accounted for 45% of the global Connected Drug Delivery Device market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects its advanced healthcare infrastructure, strong digital health adoption, and growing emphasis on patient-centric care. According to the Centers for Disease Control and Prevention (2024), over 38.4 million people, 11.6% of the U.S. population, have diabetes, creating substantial demand for connected insulin pens, insulin pumps, and automated delivery systems. The region also benefits from a robust digital health ecosystem, widespread smartphone penetration, and mobile health application usage that facilitate connected-device adoption, alongside supportive reimbursement frameworks. In April 2024, Insulet's Omnipod 5, an automated insulin delivery system that integrates with continuous glucose monitoring and can be controlled via smartphone, received approval from Health Canada. Clear regulatory pathways from the FDA and Health Canada, the presence of leading device manufacturers, and strong venture funding in health technology reinforce North America's continued leadership across the forecast period.
Fastest Growing Region: Asia-Pacific
Asia-Pacific is the fastest-growing region in the Connected Drug Delivery Device market. The region's elevated CAGR is driven by a large patient pool, rising chronic disease burden, and rapid digital health adoption across China, Japan, South Korea, and India. The International Diabetes Federation (2023) reported that China alone accounts for over 140 million people with diabetes, the world's largest diabetic population, while rising cases of asthma, COPD, and cardiovascular disease are accelerating demand for connected inhalers, insulin pens, and smart injectors. Government-driven initiatives, including China's Healthy China 2030 plan, Japan's digital health acceleration programs, and India's National Digital Health Mission, are creating strong foundations for connected-device integration, while local manufacturers increasingly collaborate with multinational device makers to expand access to affordable solutions. This combination of disease burden, digital health maturity, and policy support positions Asia-Pacific as the principal source of incremental growth over the forecast period.
Regional Commentary
North America
North America accounted for 45% of the global Connected Drug Delivery Device market revenue in 2025. The United States dominates on the strength of its advanced healthcare infrastructure, high chronic disease burden, favorable reimbursement policies, and clear FDA regulatory pathways, while the presence of leading device manufacturers and strong health-technology investment reinforce its leadership.
Europe
Europe is a large and advanced regional market, supported by strong regulatory backing from the European Medicines Agency, rising chronic disease prevalence, and growing digital health initiatives such as the European Health Data Space. Germany's DiGA reimbursement framework for digital health applications, alongside strong adoption in the United Kingdom and France, reinforces the region's position as a key growth market for connected insulin pens, smart inhalers, and wearable injectors. In July 2025, Medtronic received CE Mark approval to expand indications of its MiniMed 780G system to additional patient populations, underscoring continued regulatory momentum in the region.
Asia-Pacific
Asia-Pacific is the fastest-growing region, propelled by a large and rising chronic disease burden across China, Japan, South Korea, and India, alongside government-driven digital health initiatives and rapid healthcare infrastructure build-out. China's large diabetic population, Japan's early adoption of connected insulin delivery systems, and India's National Digital Health Mission are accelerating regional adoption and manufacturer investment.
Rest of World
The Rest of the World region, spanning the Middle East, Africa, and South America, is an emerging growth frontier. Expanding healthcare infrastructure, rising demand for chronic disease management solutions, and gradual alignment of regulatory frameworks with global digital health standards are broadening access, while growing investment from multinational device manufacturers supports the build-out of regional distribution and support networks.
Connected Drug Delivery Device Market Competitive Landscape
The Connected Drug Delivery Device market is classified as Moderately Concentrated. A mix of established medtech and pharmaceutical companies, including Medtronic, Novo Nordisk, West Pharmaceutical Services, and Merck KGaA, drive growth through strategic collaborations, product launches, and digital integration, while specialized providers such as Findair, Adherium, Propeller Health, BIOCORP, and Phillips-Medisize compete through niche innovation in smart sensors, add-on devices, and AI-powered adherence platforms.
The competitive landscape can be evaluated across the following dimensions:
In April 2025, Dexcom received FDA clearance for the G7 15-Day sensor, which offers extended wear time and enhanced accuracy for diabetes management. Strategic significance: Strengthens Dexcom's continuous glucose monitoring portfolio and extends device usability for patients.
In March 2025, Enable Injections obtained EU MDR CE mark for the enFuse Syringe Transfer System, facilitating at-home administration of biologic therapies. Strategic significance: Expands at-home biologic delivery capability and broadens the addressable therapeutic base.
In February 2025, Supernus Pharmaceuticals received FDA approval for ONAPGO, the first subcutaneous apomorphine infusion device for Parkinson's disease motor fluctuations. Strategic significance: Extends connected drug delivery into neurology, beyond the traditional diabetes and respiratory focus.
Connected Drug Delivery Device Market Segmentation
Connected Drug Delivery Device Market by Product
Canada Connected Drug Delivery Device Market Size in USD million (2023-2034)
Mexico Connected Drug Delivery Device Market Size in USD million (2023-2034)
United Kingdom Connected Drug Delivery Device Market Size in USD million (2023-2034)
France Connected Drug Delivery Device Market Size in USD million (2023-2034)
Italy Connected Drug Delivery Device Market Size in USD million (2023-2034)
Spain Connected Drug Delivery Device Market Size in USD million (2023-2034)
Rest of Europe Connected Drug Delivery Device Market Size in USD million (2023-2034)
Japan Connected Drug Delivery Device Market Size in USD million (2023-2034)
India Connected Drug Delivery Device Market Size in USD million (2023-2034)
Australia Connected Drug Delivery Device Market Size in USD million (2023-2034)
South Korea Connected Drug Delivery Device Market Size in USD million (2023-2034)
Rest of Asia-Pacific Connected Drug Delivery Device Market Size in USD million (2023-2034)
Africa Connected Drug Delivery Device Market Size in USD million (2023-2034)
South America Connected Drug Delivery Device Market Size in USD million (2023-2034)
Key Takeaways from the Connected Drug Delivery Device Market Report Study
Q1. What is the growth rate of the Connected Drug Delivery Device market?
The Connected Drug Delivery Device market is projected to expand at a CAGR of 8.9% during the forecast period from 2026 to 2034.
Q2. What is the market size of the Connected Drug Delivery Device market?
The Connected Drug Delivery Device market is estimated at USD 1.22 billion in 2025 and is projected to reach USD 7.94 billion by 2034.
Q3. Which region dominates the Connected Drug Delivery Device market?
North America dominated the Connected Drug Delivery Device market with a 45% share of global revenue in 2025, supported by an advanced healthcare infrastructure, strong digital health adoption, favorable reimbursement policies, and the presence of leading device manufacturers. Asia-Pacific is the fastest-growing region over the forecast period.
Q4. What are the key drivers of the Connected Drug Delivery Device market?
The principal drivers are the rising global burden of chronic diseases, with approximately 591 million people living with diabetes in 2025 and 263 million affected by asthma; the growth of digital health and remote patient monitoring; continuous technological advancement in device design; accelerating regulatory approvals and product launches; and strategic acquisitions and partnerships among device manufacturers and pharmaceutical companies.
Q5. Who are the major players in the Connected Drug Delivery Device market?
The major players include Findair Sp. z o. o., Adherium, Propeller Health, West Pharmaceutical Services, Inc., BIOCORP, Phillips-Medisize, Merck KGaA, Novo Nordisk A/S, Medtronic, and Tandem Diabetes Care, Inc., among other active providers profiled in the Competitive Landscape section, along with Ypsomed, Teva Pharmaceutical Industries Ltd., Elcam Medical, Cohero Health, Inc., and BD. Medtronic, Novo Nordisk A/S, West Pharmaceutical Services, and Merck KGaA lead through global distribution networks and R&D scale.
Overview
- The Connected Drug Delivery Device market is estimated at USD 1.22 billion in 2025 and is projected to reach USD 7.94 billion by 2034. Growth is anchored in the rising global burden of chronic diseases such as diabetes and asthma, the accelerating adoption of digital health and remote patient monitoring, and continuous technological advancement in smart, connected device design.
- The global Connected Drug Delivery Device market is growing at a CAGR of 23.2% during the forecast period from 2026 to 2034.
- By product, the integrated connected devices segment dominated the Connected Drug Delivery Device market with a 60% share in 2025.
- By technology, the Bluetooth segment dominated the Connected Drug Delivery Device market with a 64% share in 2025.
- By end-user, the hospitals & clinics segment dominated the Connected Drug Delivery Device market with a 55% share in 2025.
- North America dominated the global Connected Drug Delivery Device market revenue with a 45% share in 2025, representing the highest regional market share globally.
Connected Drug Delivery Device Market Key Growth Drivers
- The rising global prevalence of chronic diseases is driving demand, with approximately 591 million people worldwide living with diabetes in 2025, a figure projected to reach 854 million by 2050, and an estimated 263 million people affected by asthma.
- The growth of digital health and remote patient monitoring is expanding adoption, as connected insulin pens, smart inhalers, and wearable injectors enable real-time therapy tracking and data sharing with healthcare providers.
- Continuous technological advancement in device design, including smart sensors, Bluetooth Low Energy connectivity, automated dosing, and mobile-app integration, is improving usability, adherence, and clinical outcomes.
- A steady cadence of regulatory approvals and product launches, including the February 2025 FDA approval of Supernus Pharmaceuticals' ONAPGO and the April 2025 FDA clearance of Dexcom's G7 15-Day sensor, is expanding the addressable market.
- Strategic acquisitions and partnerships among device manufacturers and pharmaceutical companies, including Novo Nordisk's acquisition of BIOCORP and Abbott's acquisition of Bigfoot Biomedical, are consolidating connected-device capability.
- The industry-wide shift toward value-based, outcome-driven healthcare models and outcome-based reimbursement is strengthening the business case for adherence-enabling connected devices.
- The convergence of chronic disease burden, digital health expansion, device innovation, and strategic consolidation is expected to sustain strong double-digit growth in the market through 2034.
The competitive landscape is led by the following active manufacturers:
- Findair Sp. z o. o.
- Adherium
- Propeller Health
- West Pharmaceutical Services, Inc.
- BIOCORP
- Phillips-Medisize
- Merck KGaA
- Novo Nordisk A/S
- Medtronic
- Tandem Diabetes Care, Inc.
Market Drivers
Rising Global Burden of Chronic Diseases
The most fundamental driver of the Connected Drug Delivery Device market is the rising global burden of chronic diseases that require long-term, precisely timed therapy. According to DelveInsight (2025), approximately 591 million people worldwide were living with diabetes, a number projected to surge to 854 million by 2050, a 46% increase, with type 2 diabetes accounting for over 90% of cases. Connected insulin pens, smart pumps, and continuous glucose monitoring systems are becoming indispensable for maintaining glycemic control, enabling patients to track glucose trends and adhere to insulin regimens while allowing providers to remotely fine-tune therapy. Similarly, an estimated 263 million people globally are affected by asthma, creating substantial demand for connected inhalers and nebulizers that monitor medication usage and transmit adherence data to clinicians. As the prevalence of these conditions rises, the volume and complexity of connected device adoption increases in step, sustaining demand through the forecast period.
Growth of Digital Health and Remote Patient Monitoring
The broader growth of digital health and remote patient monitoring is amplifying adoption of connected drug delivery devices. By leveraging mobile apps, Bluetooth Low Energy, NFC, and cloud-based platforms, these devices provide real-time visibility into medication usage and patient health metrics, enabling proactive clinical decision-making and supporting home-based care. This connectivity reduces the need for frequent hospital visits while giving healthcare providers continuous access to adherence and outcome data. For instance, in February 2025, Supernus Pharmaceuticals received FDA approval for ONAPGO, the first subcutaneous apomorphine infusion device for Parkinson's disease motor fluctuations, illustrating the expanding therapeutic scope of connected devices beyond diabetes and respiratory care.
Market Restraints
Despite strong momentum, the Connected Drug Delivery Device market faces material constraints. Data privacy and cybersecurity concerns are significant, as connected devices continuously transmit sensitive patient health information across mobile apps and cloud platforms, exposing manufacturers and providers to breach risk and regulatory scrutiny. The environmental impact of electronic waste from single-use and short-lifecycle connected components raises sustainability concerns and is drawing increasing regulatory attention. The relatively high price of connected devices compared with conventional, non-connected alternatives can limit adoption in cost-sensitive markets and among uninsured or underinsured patients. Interoperability challenges across competing Bluetooth, NFC, and proprietary platforms complicate integration with electronic health record systems, while building the digital health infrastructure and physician training needed for widespread adoption remains uneven across geographies. Together, these data-security, environmental, affordability, and infrastructure barriers temper the pace of growth, even as the underlying drivers of chronic disease burden, digital health expansion, and device innovation remain firmly intact.
Connected Drug Delivery Device Market Segment Analysis
The connected drug delivery device market by product (connected sensors [connected inhaler sensors and connectable injection sensors] and integrated connected devices [connected inhaler devices and connected injectable devices]), technology (Bluetooth, near-field communication (NFC), and others), end-user (hospitals & clinics, homecare settings, and others), and geography (North America, Europe, Asia-Pacific, and Rest of World).
By Product
Dominant Subsegment: Integrated Connected Devices.
The integrated connected devices segment accounted for 60% of the Connected Drug Delivery Device market in 2025. Within this segment, connected injectable devices hold the largest share, driven by the widespread adoption of smart insulin pens, auto-injectors, and wearable injectors. These devices are becoming the preferred choice for chronic disease management because they improve medication adherence, ensure precise dosing, and enable real-time monitoring of treatment outcomes. The incorporation of Bluetooth, NFC, and cloud-based platforms allows connected injectors to seamlessly transmit patient data to healthcare providers, enabling timely clinical interventions and personalized therapy adjustments, particularly for chronic conditions such as diabetes, multiple sclerosis, and rheumatoid arthritis. By facilitating at-home administration, connected injectable devices also reduce dependency on hospital visits, improving patient convenience and easing healthcare system burden. Ongoing innovation, including integrated sensors for dose verification and interoperability with mobile health apps and electronic health records, such as Medtronic's November 2024 FDA-cleared InPen update with missed meal dose detection, is further accelerating adoption. While connected sensors are growing steadily as an add-on retrofit category, the breadth, precision, and clinical integration of integrated connected devices secure the segment's leadership across the forecast period.
By Technology
Dominant Subsegment: Bluetooth.
The Bluetooth segment accounted for 64% of the Connected Drug Delivery Device market in 2025. The widespread adoption of Bluetooth, particularly Bluetooth Low Energy, has positioned it as the leading connectivity technology because of its low power consumption, seamless integration with smartphones, and ability to support real-time data transmission. Devices such as smart insulin pens, connected inhalers, and wearable injectors leverage Bluetooth to sync with mobile applications, enabling patients to track adherence, receive personalized reminders, and share treatment data with healthcare providers. For example, in May 2025, Oura introduced the Stelo glucose biosensor, a wearable device using Bluetooth to deliver real-time glucose data integrated into a broader health app, reinforcing the value of Bluetooth-enabled health ecosystems. Compared with NFC and other connectivity standards, Bluetooth remains the preferred choice because of its ubiquity across consumer devices, compatibility with digital health platforms, and reliable operation without continuous internet connectivity. Ongoing advancements in Bluetooth Low Energy protocols, offering extended range and improved energy efficiency, are expected to further reinforce its dominant position across the forecast period.
Connected Drug Delivery Device Market Region Analysis
Dominant Region: North America
North America accounted for 45% of the global Connected Drug Delivery Device market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects its advanced healthcare infrastructure, strong digital health adoption, and growing emphasis on patient-centric care. According to the Centers for Disease Control and Prevention (2024), over 38.4 million people, 11.6% of the U.S. population, have diabetes, creating substantial demand for connected insulin pens, insulin pumps, and automated delivery systems. The region also benefits from a robust digital health ecosystem, widespread smartphone penetration, and mobile health application usage that facilitate connected-device adoption, alongside supportive reimbursement frameworks. In April 2024, Insulet's Omnipod 5, an automated insulin delivery system that integrates with continuous glucose monitoring and can be controlled via smartphone, received approval from Health Canada. Clear regulatory pathways from the FDA and Health Canada, the presence of leading device manufacturers, and strong venture funding in health technology reinforce North America's continued leadership across the forecast period.
Fastest Growing Region: Asia-Pacific
Asia-Pacific is the fastest-growing region in the Connected Drug Delivery Device market. The region's elevated CAGR is driven by a large patient pool, rising chronic disease burden, and rapid digital health adoption across China, Japan, South Korea, and India. The International Diabetes Federation (2023) reported that China alone accounts for over 140 million people with diabetes, the world's largest diabetic population, while rising cases of asthma, COPD, and cardiovascular disease are accelerating demand for connected inhalers, insulin pens, and smart injectors. Government-driven initiatives, including China's Healthy China 2030 plan, Japan's digital health acceleration programs, and India's National Digital Health Mission, are creating strong foundations for connected-device integration, while local manufacturers increasingly collaborate with multinational device makers to expand access to affordable solutions. This combination of disease burden, digital health maturity, and policy support positions Asia-Pacific as the principal source of incremental growth over the forecast period.
Regional Commentary
North America
North America accounted for 45% of the global Connected Drug Delivery Device market revenue in 2025. The United States dominates on the strength of its advanced healthcare infrastructure, high chronic disease burden, favorable reimbursement policies, and clear FDA regulatory pathways, while the presence of leading device manufacturers and strong health-technology investment reinforce its leadership.
Europe
Europe is a large and advanced regional market, supported by strong regulatory backing from the European Medicines Agency, rising chronic disease prevalence, and growing digital health initiatives such as the European Health Data Space. Germany's DiGA reimbursement framework for digital health applications, alongside strong adoption in the United Kingdom and France, reinforces the region's position as a key growth market for connected insulin pens, smart inhalers, and wearable injectors. In July 2025, Medtronic received CE Mark approval to expand indications of its MiniMed 780G system to additional patient populations, underscoring continued regulatory momentum in the region.
Asia-Pacific
Asia-Pacific is the fastest-growing region, propelled by a large and rising chronic disease burden across China, Japan, South Korea, and India, alongside government-driven digital health initiatives and rapid healthcare infrastructure build-out. China's large diabetic population, Japan's early adoption of connected insulin delivery systems, and India's National Digital Health Mission are accelerating regional adoption and manufacturer investment.
Rest of World
The Rest of the World region, spanning the Middle East, Africa, and South America, is an emerging growth frontier. Expanding healthcare infrastructure, rising demand for chronic disease management solutions, and gradual alignment of regulatory frameworks with global digital health standards are broadening access, while growing investment from multinational device manufacturers supports the build-out of regional distribution and support networks.
Connected Drug Delivery Device Market Competitive Landscape
The Connected Drug Delivery Device market is classified as Moderately Concentrated. A mix of established medtech and pharmaceutical companies, including Medtronic, Novo Nordisk, West Pharmaceutical Services, and Merck KGaA, drive growth through strategic collaborations, product launches, and digital integration, while specialized providers such as Findair, Adherium, Propeller Health, BIOCORP, and Phillips-Medisize compete through niche innovation in smart sensors, add-on devices, and AI-powered adherence platforms.
The competitive landscape can be evaluated across the following dimensions:
- Market concentration: Moderately concentrated, with established medtech and pharmaceutical leaders alongside a fast-growing field of specialized digital-health device makers.
- Leading players: Medtronic, Novo Nordisk A/S, West Pharmaceutical Services, and Merck KGaA anchor the top tier through global distribution networks and R&D scale.
- Geographic reach: Leaders operate global, multi-country distribution and manufacturing networks that support both hospital and homecare channels across major markets.
- Product portfolio strength: Top players offer end-to-end connected sensor and integrated device portfolios spanning inhalers, injectors, and insulin delivery systems.
- Connectivity and platform access: Ownership of proprietary Bluetooth and NFC-enabled platforms, and integration with mobile health apps and electronic health records, is a decisive advantage.
- Strategic partnerships: Tie-ups between pharmaceutical companies and device makers, such as Abbott's collaboration with Medtronic and Sequel Med Tech's partnership with Senseonics, extend platform reach.
- M&A activity: Active consolidation, including Novo Nordisk's acquisition of BIOCORP and Abbott's acquisition of Bigfoot Biomedical, is reshaping the competitive landscape.
- Manufacturing capabilities: Precision sensor manufacturing, automated dosing mechanisms, and app-integrated firmware development are key competitive moats.
- Innovation focus: AI-driven adherence analytics, glucose-responsive smart insulin, wearable delivery systems, and implantable long-wear sensors.
In April 2025, Dexcom received FDA clearance for the G7 15-Day sensor, which offers extended wear time and enhanced accuracy for diabetes management. Strategic significance: Strengthens Dexcom's continuous glucose monitoring portfolio and extends device usability for patients.
In March 2025, Enable Injections obtained EU MDR CE mark for the enFuse Syringe Transfer System, facilitating at-home administration of biologic therapies. Strategic significance: Expands at-home biologic delivery capability and broadens the addressable therapeutic base.
In February 2025, Supernus Pharmaceuticals received FDA approval for ONAPGO, the first subcutaneous apomorphine infusion device for Parkinson's disease motor fluctuations. Strategic significance: Extends connected drug delivery into neurology, beyond the traditional diabetes and respiratory focus.
Connected Drug Delivery Device Market Segmentation
Connected Drug Delivery Device Market by Product
- Connected Sensors
- Connected Inhaler Sensors
- Connectable Injection Sensors
- Integrated Connected Devices
- Connected Inhaler Devices
- Connected Injectable Devices
- Bluetooth
- Near-Field Communication (NFC)
- Others
- Hospitals & Clinics
- Homecare Settings
- Others
- North America Connected Drug Delivery Device Market
Canada Connected Drug Delivery Device Market Size in USD million (2023-2034)
Mexico Connected Drug Delivery Device Market Size in USD million (2023-2034)
- Europe Connected Drug Delivery Device Market
United Kingdom Connected Drug Delivery Device Market Size in USD million (2023-2034)
France Connected Drug Delivery Device Market Size in USD million (2023-2034)
Italy Connected Drug Delivery Device Market Size in USD million (2023-2034)
Spain Connected Drug Delivery Device Market Size in USD million (2023-2034)
Rest of Europe Connected Drug Delivery Device Market Size in USD million (2023-2034)
- Asia-Pacific Connected Drug Delivery Device Market
Japan Connected Drug Delivery Device Market Size in USD million (2023-2034)
India Connected Drug Delivery Device Market Size in USD million (2023-2034)
Australia Connected Drug Delivery Device Market Size in USD million (2023-2034)
South Korea Connected Drug Delivery Device Market Size in USD million (2023-2034)
Rest of Asia-Pacific Connected Drug Delivery Device Market Size in USD million (2023-2034)
- Rest of the World (RoW) Connected Drug Delivery Device Market
Africa Connected Drug Delivery Device Market Size in USD million (2023-2034)
South America Connected Drug Delivery Device Market Size in USD million (2023-2034)
Key Takeaways from the Connected Drug Delivery Device Market Report Study
- Market size analysis for the current Connected Drug Delivery Device market size (2025), and market forecast for 9 years (2026 to 2034).
- Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
- Key companies dominating the global Connected Drug Delivery Device market.
- Various opportunities available for competitors in the Connected Drug Delivery Device market space.
- What are the top-performing segments in 2025? How will these segments perform in 2034?
- Which are the top-performing regions and countries in the current Connected Drug Delivery Device market scenario?
- Which are the regions and countries where companies should concentrate their opportunities for Connected Drug Delivery Device market growth in the future?
- Connected Drug Delivery Device product providers
- Research organizations and consulting companies
- Connected Drug Delivery Device -related organizations, associations, forums, and other alliances
- Government and corporate offices
- Start-up companies, venture capitalists, and private equity firms
- Distributors and traders dealing in Connected Drug Delivery Devices
- Various end-users who want to know more about the Connected Drug Delivery Device market and the latest technological developments in the Connected Drug Delivery Device market.
Q1. What is the growth rate of the Connected Drug Delivery Device market?
The Connected Drug Delivery Device market is projected to expand at a CAGR of 8.9% during the forecast period from 2026 to 2034.
Q2. What is the market size of the Connected Drug Delivery Device market?
The Connected Drug Delivery Device market is estimated at USD 1.22 billion in 2025 and is projected to reach USD 7.94 billion by 2034.
Q3. Which region dominates the Connected Drug Delivery Device market?
North America dominated the Connected Drug Delivery Device market with a 45% share of global revenue in 2025, supported by an advanced healthcare infrastructure, strong digital health adoption, favorable reimbursement policies, and the presence of leading device manufacturers. Asia-Pacific is the fastest-growing region over the forecast period.
Q4. What are the key drivers of the Connected Drug Delivery Device market?
The principal drivers are the rising global burden of chronic diseases, with approximately 591 million people living with diabetes in 2025 and 263 million affected by asthma; the growth of digital health and remote patient monitoring; continuous technological advancement in device design; accelerating regulatory approvals and product launches; and strategic acquisitions and partnerships among device manufacturers and pharmaceutical companies.
Q5. Who are the major players in the Connected Drug Delivery Device market?
The major players include Findair Sp. z o. o., Adherium, Propeller Health, West Pharmaceutical Services, Inc., BIOCORP, Phillips-Medisize, Merck KGaA, Novo Nordisk A/S, Medtronic, and Tandem Diabetes Care, Inc., among other active providers profiled in the Competitive Landscape section, along with Ypsomed, Teva Pharmaceutical Industries Ltd., Elcam Medical, Cohero Health, Inc., and BD. Medtronic, Novo Nordisk A/S, West Pharmaceutical Services, and Merck KGaA lead through global distribution networks and R&D scale.
Table of Contents
150 Pages
- 1. Connected Drug Delivery Device Market Report Introduction
- 1.1 Scope of the Study
- 1.2 Market Segmentation
- 1.3 Market Assumptions
- 2. Connected Drug Delivery Device Market Executive Summary
- 2.1 Market at a Glance
- 3. Connected Drug Delivery Device Market Key Factors Analysis
- 3.1 Connected Drug Delivery Device Market Drivers
- 3.1.1 Rising Global Burden of Chronic Diseases
- 3.1.2 Growth of Digital Health and Remote Patient Monitoring
- 3.1.3 Technological Advancements in Device Design
- 3.1.4 Strategic Acquisitions and Partnerships
- 3.2 Connected Drug Delivery Device Market Restraints and Challenges
- 3.2.1 Data Privacy and Cybersecurity Concerns
- 3.2.2 Device Affordability and Environmental Concerns
- 3.2.3 Interoperability and Infrastructure Complexity
- 3.3 Connected Drug Delivery Device Market Opportunities
- 3.3.1 Expansion into New Therapeutic Areas
- 3.3.2 Emerging-Market and Homecare Expansion
- 4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
- 5. Regulatory Analysis
- 5.1 United States
- 5.2 Europe
- 5.3 Japan
- 5.4 China
- 6. Connected Drug Delivery Device Market Porter's Five Forces Analysis
- 6.1 Bargaining Power of Suppliers
- 6.2 Bargaining Power of Buyers
- 6.3 Threat of New Entrants
- 6.4 Threat of Substitutes
- 6.5 Competitive Rivalry
- 7. Connected Drug Delivery Device Market Assessment
- 7.1 By Product
- 7.1.1 Connected Sensors
- 7.1.1.1 Connected Inhaler Sensors
- 7.1.1.2 Connectable Injection Sensors
- 7.1.2 Integrated Connected Devices
- 7.1.2.1 Connected Inhaler Devices
- 7.1.2.2 Connected Injectable Devices
- 7.2 By Technology
- 7.2.1 Bluetooth
- 7.2.2 Near-Field Communication (NFC)
- 7.2.3 Others
- 7.3 By End-Users
- 7.3.1 Hospitals & Clinics
- 7.3.2 Homecare Settings
- 7.3.3 Others
- 7.4 By Geography
- 7.4.1 North America
- 7.4.1.1 United States Connected Drug Delivery Device Market Size in USD million (2023-2034)
- 7.4.1.2 Canada Connected Drug Delivery Device Market Size in USD million (2023-2034)
- 7.4.1.3 Mexico Connected Drug Delivery Device Market Size in USD million (2023-2034)
- 7.4.2 Europe
- 7.4.2.1 Germany Connected Drug Delivery Device Market Size in USD million (2023-2034)
- 7.4.2.2 United Kingdom Connected Drug Delivery Device Market Size in USD million (2023-2034)
- 7.4.2.3 France Connected Drug Delivery Device Market Size in USD million (2023-2034)
- 7.4.2.4 Italy Connected Drug Delivery Device Market Size in USD million (2023-2034)
- 7.4.2.5 Spain Connected Drug Delivery Device Market Size in USD million (2023-2034)
- 7.4.2.6 Rest of Europe Connected Drug Delivery Device Market Size in USD million (2023-2034)
- 7.4.3 Asia-Pacific
- 7.4.3.1 China Connected Drug Delivery Device Market Size in USD million (2023-2034)
- 7.4.3.2 Japan Connected Drug Delivery Device Market Size in USD million (2023-2034)
- 7.4.3.3 India Connected Drug Delivery Device Market Size in USD million (2023-2034)
- 7.4.3.4 Australia Connected Drug Delivery Device Market Size in USD million (2023-2034)
- 7.4.3.5 South Korea Connected Drug Delivery Device Market Size in USD million (2023-2034)
- 7.4.3.6 Rest of Asia-Pacific Connected Drug Delivery Device Market Size in USD million (2023-2034)
- 7.4.4 Rest of World
- 7.4.4.1 Middle East Connected Drug Delivery Device Market Size in USD million (2023-2034)
- 7.4.4.2 Africa Connected Drug Delivery Device Market Size in USD million (2023-2034)
- 7.4.4.3 South America Connected Drug Delivery Device Market Size in USD million (2023-2034)
- 8. Connected Drug Delivery Device Market Competitive Landscape
- 8.1 Market Concentration and Structure
- 8.2 Competitive Positioning and Market Share Analysis (Premium Offering)
- 9. Connected Drug Delivery Device Market Startup Funding and Investment Trends
- 10. Connected Drug Delivery Device Market Company and Product Profiles
- 10.1 Findair Sp. z o. o.
- 10.1.1 Company Overview
- 10.1.2 Company Snapshot
- 10.1.3 Financial Overview
- 10.1.4 Service Portfolio
- 10.1.5 Strategic Initiatives / Entropy
- 10.2 Adherium
- 10.2.1 Company Overview
- 10.2.2 Company Snapshot
- 10.2.3 Financial Overview
- 10.2.4 Product Portfolio
- 10.2.5 Strategic Initiatives / Entropy
- 10.3 Propeller Health
- 10.3.1 Company Overview
- 10.3.2 Company Snapshot
- 10.3.3 Financial Overview
- 10.3.4 Product Portfolio
- 10.3.5 Strategic Initiatives / Entropy
- 10.4 West Pharmaceutical Services, Inc.
- 10.4.1 Company Overview
- 10.4.2 Company Snapshot
- 10.4.3 Financial Overview
- 10.4.4 Product Portfolio
- 10.4.5 Strategic Initiatives / Entropy
- 10.5 BIOCORP
- 10.5.1 Company Overview
- 10.5.2 Company Snapshot
- 10.5.3 Financial Overview
- 10.5.4 Product Portfolio
- 10.5.5 Strategic Initiatives / Entropy
- 10.6 Phillips-Medisize
- 10.6.1 Company Overview
- 10.6.2 Company Snapshot
- 10.6.3 Financial Overview
- 10.6.4 Product Portfolio
- 10.6.5 Strategic Initiatives / Entropy
- 10.7 Merck KGaA
- 10.7.1 Company Overview
- 10.7.2 Company Snapshot
- 10.7.3 Financial Overview
- 10.7.4 Product Portfolio
- 10.7.5 Strategic Initiatives / Entropy
- 10.8 Novo Nordisk A/S
- 10.8.1 Company Overview
- 10.8.2 Company Snapshot
- 10.8.3 Financial Overview
- 10.8.4 Product Portfolio
- 10.8.5 Strategic Initiatives / Entropy
- 10.9 Medtronic
- 10.9.1 Company Overview
- 10.9.2 Company Snapshot
- 10.9.3 Financial Overview
- 10.9.4 Product Portfolio
- 10.9.5 Strategic Initiatives / Entropy
- 10.10 Tandem Diabetes Care, Inc.
- 10.10.1 Company Overview
- 10.10.2 Company Snapshot
- 10.10.3 Financial Overview
- 10.10.4 Product Portfolio
- 10.10.5 Strategic Initiatives / Entropy
- For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.
- 11. KOL Views
- 12. Project Approach
- 13. About DelveInsight
- 14. Disclaimer and Contact Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
